Under a tenth of people that would benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it issues its inaugural advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our new guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to universal access to the jabs that can help people shift substantial body mass, says the organization.
Weight-Loss Drug Shortage
Despite the present most favorable outlook, the production of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.
The advice encourages nations and manufacturers to expand availability, through measures including voluntary licensing.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Jabs Function
These medications mimick a biological compound to reduce digestion speed, reduce hunger and boost satiety so users eat less.
Individuals commonly start to lose weight in the initial weeks of beginning the once-weekly jabs.
Evidence suggests people may see weight return within a year of discontinuing the treatment, when their normal food cravings come back.
Being overweight or obese raises your risk for developing health problems, like type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity affects individuals in every country and was associated with millions of deaths worldwide in 2024, according to the WHO.
